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 Introduction:
Since the introduction of steroid eluting electrodes, the incidence of an early massive rise in the 
capture threshold that either exceeds or threatens to exceed the programmed output of the 
pacemaker has declined but has not totally disappeared1  If a persistent or massive threshold rise 
is encountered in the days to months post-implant, one consideration is microinstability of the 
lead.   In this setting, there may be a change in the morphology of the pacemaker evoked 
depolarization on the ECG or a change in the physical location of the lead as assessed with a 
chest x-ray.  Another marker is fluctuations in the capture threshold on repeated assessments at 
the same office or clinic visit. The options for this problem include an operative procedure to 
reposition or replace the lead or to closely observe the patient hoping that the lead settles into a 
secure location. Another potential totally reversible cause is the introduction of an new 
medication or herb. If the possible explanations for threshold increase cited above have been 
excluded and the high capture threshold is believed to be due to lead maturation, increasing the 
output   or   possible   lead   replacement   or   repositioning   have   been   the   usual   options.
                A massive capture threshold rise encountered years post-implant is not associated with 
the acute inflammatory process at the electrode-tissue interface although there is one report in 
the literature of prednisolone effectively treating a threshold rise occurring two years post-
implant2  The threshold rise in this situation is probably due to either a primary myocardial 
process resulting in increased fibrosis or scarring at the electrode-tissue interface or a mechanical 
problem (conductor fracture or damage to the insulation) developing with the lead.   In both of 
these settings, if an adequate safety margin cannot be maintained by increasing the programmed 
output, the lead will need to be replaced.                                                                         
                In the mid-1960's, Dr. Preston and colleagues published a number of papers reporting 
the impact of various pharmacologic agents and physiologic factors on capture thresholds3,4.  
This was further elaborated upon by both these authors5  and Dr. Sowton6  at a conference 
devoted to the emerging science of cardiac pacing.   Glucocorticoids were reported reduce 
capture thresholds.   As these are also very potent anti-inflammatory agents, it was further 
postulated that by reducing if not eliminating the acute inflammatory process that accounted for 
a significant component of the threshold rise during the lead maturation process, one might also 
use systemic steroids to treat the early massive rise in capture thresholds.  It was these early 
reports that led to the introduction of steroid (dexamethasone sodium phosphate) into the tip of 
the modern electrode.   The results have been superb with a marked blunting in the post-implant 
rise in capture threshold even though this has not been totally eliminated1.  Despite the routine 
use of steroid eluting electrodes at this time, the physician will still encounter a rare patient with 
an unexpected massive rise in the capture threshold.   
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Over the years, based on an occasional patient whom I am following but more often, at the 
request of another physician calling to discuss management of a patient with a massive rise in the 
capture threshold during the lead maturation period (up to 6 months post-implant), I have either 
tried or recommended a course of oral steroids before proceeding with an operative intervention.  
This has been anecdotally successful in approximately 50% of the patients.  If effective, it may 
eliminate the need for an operative intervention.
I have both used and recommended the following protocol.  It has NOT been subjected to a 
formal double blind prospective randomized placebo-controlled trial. As such, it must be 
considered totally empiric. It is unknown whether the "beneficial effect" is actually coincidence 
having initiated steroids at the peak of the threshold maturation curve which would have started 
to decline on its own or a true effect.    
 Protocol: 
1.  Detailed assessment of the capture threshold.  If the pulse amplitude and pulse width 
programmability of the pacemaker allow, a full strength duration curve should be 
obtained.  Also obtain a sensing threshold.   [Note: the acute inflammatory reaction at the 
electrode-tissue interface will cause a rise in the capture threshold and deterioration in the 
sensing threshold.]                         
2. Initiate a trial of Prednisone at 1 mg/kg or 60 mg/day- which ever is lower.  This may be 
given in divided doses.  This presupposes the absence of a contraindication to systemic 
steroids.                  
3. Repeat the capture and sensing threshold assessment in 4 to 5 days.   If there is  NO 
change in these thresholds at this evaluation, the steroid is unlikely to be effective and it 
is recommended that this medication be discontinued.  This is too short a time for adrenal 
suppression to occur and tapering is not required. 
4. If there has been a significant drop in the capture threshold (defined as a decrease in at 
least two programming steps - either pulse width and/or pulse amplitude), the current 
dose of prednisone should be continued for a minimum of 1 month.   
5. Capture and sensing thresholds should be tracked on a biweekly basis after demonstrating 
the initial improvement.                                                            
6. At the end of 1 month on the relatively high prednisone dose, begin to slowly taper the 
steroids planning to discontinue them after a 2 month course of slow tapering.                
7. During this time, it is important to closely monitor capture and sensing threshold. If these 
are demonstrated to deteriorate, the prednisone dose should be increased for a couple of 
weeks and tapering only resumed after the thresholds are shown to again improve.  
8. If the steroid is initially ineffective or effective but the threshold does not fall to a 
sufficiently low level such that lead repositioning is planned, the likelihood of a high 
threshold occurring with the second procedure is in the range of 4 to 5%.   My 
recommendation would be to use a new lead rather than trying to reposition the current 
lead. If a steroid-eluting lead had not been used on the first procedure, one should be used 
at this time.  If a steroid-eluting lead had been used on the initial procedure, a new lead 
should still be used as traction on the original lead to disengage it from the primary 
position may disrupt the mechanical integrity of the lead predisposing to late problems.  
Damage to the lead may not be immediately apparent upon testing with a Pacing System 
Analyzer.  In both cases, I recommend the use of a steroid-eluting active fixation  lead  so
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that the electrode can be positioned in an area remote from the original location. 
9. If the decision is made to proceed with a repeat operative procedure involving either 
replacement or repositioning of the lead, a venogram is strongly recommended.  This 
should be performed just prior to the procedure to determine if the central venous system 
is patent and will allow repeat access for placement of a new lead.  
Caution:    
Possible side effects that are associated with a protracted course of high dose steroid therapy 
include but are not limited to suppression of the adrenal and pituitary glands, impairment of 
immunocompetence and thus predisposition to infections, impairment of wound healing, 
exacerbation of peptic ulcer disease, acceleration of osteoporosis, induction of fluid retention and 
electrolyte imbalance, and exacerbation of diabetes mellitus.  The Physician's Desk Reference or 
a major pharmacology text should be checked if one is not sure of all the potential complications 
associated with systemic steroid therapy.  The patient should be both evaluated and followed for 
the potential complications associated with systemic steroids during the course of this treatment.  
If a complication develops, it will be a clinical decision to either treat the complications and 
continue the steroids or to discontinue the steroids.  The physician must determine whether the 
potential benefits to be gained from the use of systemic steroids outweigh the theoretical risks vs 
the potential for loss of capture and need for a repeat operation. 
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